|
|
TOP NEWS
Wuxi Pharma Tech
|
 13/05/2010
[Company watch]
WuXi PharmaTech Reports Strong Q1 Revenues
WuXi PharmaTech reported Q1 revenues rose 36% to $80.6 million, helped by a very large increase in its contract manufacturing division, which grew 433% to $13.6 million. In WuXi’s core Lab Services business, revenues were up 18%. GAAP net income climbed 32% to $15.5 million or 21 cents per share.
|
| |
|
WuXi PharmaTech reported Q1 revenues rose 36% to $80.6 million, helped by a very large increase in its contract manufacturing division, which grew 433% to $13.6 million. In WuXi’s core Lab Services business, revenues were up 18%. GAAP net income climbed 32% to $15.5 million or 21 cents per share.
The company showed some optimism about the rest of the year. It now expects full-year 2010 revenues to be at the high end of its previous $310-$320 million forecast, about an 18-19% growth rate. China-based lab services will increase about 15% while revenues from manufacturing will jump at least 70%.
WuXi also pointed out that its laboratory business was higher because of increased offerings such as DMPK/ADME, biology, process research, formulation and analytical services. It said manufacturing was strong because of delivery of a single large project and increasing demand. On the other hand, startup costs of its Suzhou toxicology facility had a negative effect on earnings.
In late April, WuXi agreed to be acquired by Charles River Labs (NYSE: CRL) for $1.6 billion. The two companies expect the transaction to close in Q4 of 2010. |
|
|
|
|
